GENE ONLINE|News &
Opinion
Blog

2021-03-31| Asia-Pacific

Korea Made Humira Biosimilar Begins Sales in Australia, Marks its Presence in Third Overseas Market

by Tyler Chen
Share To

After launching in Canada in February, Korea’s Samsung Bioepis began selling HUMIRA’s biosimilar HADLIMA (adalimumab) in Australia in partnership with MSD Australia (Merck & Co. in the U.S. and Canada).

 

What is Adalimumab?

Adalimumab is an anti-TNF biosimilar of AbbVie’s hot-selling drug Humira that is approved for numerous indications. They include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and plaque psoriasis.

Adalimumab is Samsung Bioepis’s third anti-TNF biosimilar approved in the US, following BRENZYS (etanercept) and RENFLEXIS (infliximab) in 2016 and 2017 respectively. Meanwhile, adalimumab is also Samsung Bioepis’s fourth biosimilar overall to be approved in the US after RENFLEXIS, ONTRUZANT (trastuzumab-dttb), and ETICOVO (etanercept-ykro).

 

Collaboration with Biogen and Merck & Co.

Before entering the market in Australia, adalimumab was firstly sold under the name of IMRALDI in Europe in 2018 in partnership with Biogen.

It was then launched in Canada working with Merck Canada in February 2021. This came after Samsung Bioepis’ agreement with Merck & Co. in 2013 where Samsung Bioepis will be in charge of clinical trials, manufacturing, and regulatory registration of the drug, and Merck & Co. will handle the commercialization and approval in partnered countries.

 

Clinical Trial Data Leading to FDA Approval

Adalimumab is currently approved in 6 countries: Australia, Canada, Europe, Switzerland, the US, and Korea. The FDA approval is a result of positive data from a Phase 3 clinical trial conducted in 544 patients with moderate to severe rheumatoid arthritis despite methotrexate (MTX) therapy.

After randomly receiving adalimumab or the reference product in Week 24, the drug arm expressed a similar response rate with the reference group (72.4% vs. 72.2%). The efficacy, safety, and immunogenicity profiles of the drug were comparable to that of the reference.

Related Article: Lilly Partners with Samsung Biologics to Boost Delivery of COVID-19 Antibody Treatments

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top